FDA Opts For Full, Rather Than Accelerated, Approval Of GSK’s Votrient In Sarcoma
This article was originally published in The Pink Sheet Daily
Executive Summary
Despite advisory committee discussion about a possible accelerated approval for pazopanib with a confirmatory study to assess symptom benefit, the agency opted to grant regular approval, as had been requested by GlaxoSmithKline.